We describe a thin-layer chromatographic technique suitablefor isolating at least four metabolites of L-aacetyl methadol. The metabolites are discussed in terms of their color reactions to chromatography spray reagents and their appearance in the urine during various time intervals after dosage. Methadone is detected by the presence of the unmetabolized drug and two of its metabolites in the urine. We present a simple means of distinguishing methadone-containing specimens from those that contain L-a-acetyl methadol. Results of an immunoassay for methadone applied to specimens from patients receiving L-a-acetyl methadol or methadone are discussed. The method is suitable as a routine screening procedure for most laboratories that use thinlayer chromatography.
toxicology #{149} screening #{149} drug abuse L-a-Acetyl methadol (LAAM) has been considered as a substitute for methadone in the maintenance of narcotics addicts (1, 2). The possibility of its largescale use is currently being evaluated in an extensive cooperative study between the Veterans Administration and the Special Action Office for Drug Abuse Prevention.
There are numerous advantages to the use of LAAM. Because it is long acting, fewer visits to the clinic are required and the need for take-home doses is eliminated.
The drug can be administered by a nurse or other authorized person, and thus an existing program can be expanded to accommodate more patients without increasing the number of staff members. The patient is benefited by becoming less involved in drug-seeking behavior and by being able to spend his time more advantageously in attending school or supporting his family. A decreased traffic in illicit methadone benefits the community. A first need in the cooperative study was for an analytical method that would provide information on the extent of drug abuse by patients participating in the program. We have applied a thin-layer chromatographic method based on Davidow's procedure (3), by which specimens may be analyzed for LAAM metabolites and a wide range of other drugs. The thinlayer method is complemented by an enzyme-immunoassay (4-7) that is sensitive to 0.5 tg of methadone hydrochloride per milliliter of urine. Dilute 200 l of the methadone stock solution to 5 ml with distilled water.
Materials and Methods

Apparatus
Maximum working standard (12.5 tg/ml final concentration).
Dilute 2 ml of the methadone stock solution to 4 ml with distilled water.
Enzyme Multiplied Immunoassay Technique (EMIT)2 Apparatus
The apparatus for EMIT described by Schneider et al. (5) is used without modification.
The reagents are supplied by the Syva Corporation.
Methods
Extraction and chromatography.
Add 25 l of each of the working standard solutions to separate culture tubes containing 10 ml of drug-free urine and mix. Add 1.0 ml of the NH4C1 buffer to all of the tubes to be used in the assay. Using one of the standard tubes as a visual reference, add about 10 ml of urine unknowns to each tube. Dispense extracting solvent to fill the tubes, using a setting of 28 to 31 ml on the Repipet. Cap the tubes and shake them on an automatic shaker at 280 strokes per minute for 1 mm. Centrifuge at 1200 rpm for 5 mm and aspirate and discard the aqueous (upper) phase. Dry the organic phase by filtering it through coarse filter paper into a 50-ml conical centrifuge tube. Add a small chip of a crushed boiling granule and evaporate the extract in a water bath at 70 #{176}C. Use a Pasteur pipet to wash the sides of the tube with about 1 ml of methanol. Evaporate the alcohol, reconstitute the residue in two drops of methanol by rolling the warm tube gently at an angle, and spot the extract on a chromatography plate. Develop the plate to 10 cm above the point of application (about 25 mm) and allow it to dry in a fume hood.
Color development.
Heat the plate at 70 #{176}C for 10 mm and spray it with ninhydrin while it is still warm. Mark any pink or purple spots and expose the plate to short-wave ultraviolet light in a portable darkroom for 4 to 5 mm. Spray the plate with the iodoplatinate reagent, allow it to dry and spray with Dragendorff reagent.
EMIT procedure. Table demonstrates that the LAAM metabolite at the same R ' does not react with ninhydrin.
The number of detectable LAAM metabolites in urine appears to depend on the time interval between ingestion of the drug and collection of the specimen. Kaistha and Jaffe (8) detected the presence of two metabolites in urine by thin-layer chromatography. The four metabolites that we have detected appear at various times up to 72 h after the ingestion of LAAM. The metabolite that is reactive to ninhydrin plus ultraviolet light at R F 0.53 is detected up to about 24 h, but it is not always observed. We have not determined the optimum collection time for isolating this metabolite as yet, but we have observed that it is always detected in the presence of the metabolite at R F 0.60. The metabolite at R F 0.60 is the major extractable metabolite during the first 24 h and its concentration gradually decreases as the final metabolites at R F 0.68 and R F 0.78 begin to be detected. These metabolites are detected up to at least 48 h after ingestion of the drug. Table 1 illustrates that unmetabolized LAAM is detected at RF 0.78, but we do not think that the corresponding spot that is detected in chromatography of the urine of LAAM patients is this compound because of its late appearance in the urine. This finding is consistent with the observation of Kaiko and Inturrisi (9) that less than 2% of the drug is excreted unmetabolized.
The metabolite detected at R F 0.60 is the most characteristic metabolite of LAAM, but its detection depends on the hour of specimen collection after the dose, and it may not be detected in urine of a patient 
Enzyme Immunoassay
The EMIT assay is based on a competitive-binding process between an antibody-drug-enzyme complex and an antigen (the drug in the urine). The enzyme in this complex is inactive because of steric hindrance by the large antibody molecules located near the active site. When antigen is present, some antibody is made unavailable for binding to the drug-enzyme. The amount (activity) of unbound enzyme, measured spectrophotometrically, is proportional to the amount of drug in the urine. The method is rapid because urine specimens can be tested directly without any previous extraction or other treatment. The assay is useful for the direct analysis of specimens that contain compounds that may interfere with the thin -layer chromatographic determination of methadone but do not interfere with the EMIT assay. 
